Literature DB >> 15276462

Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence.

Giulio Selvetella1, Emilio Hirsch, Antonella Notte, Guido Tarone, Giuseppe Lembo.   

Abstract

Myocardial hypertrophy is a response of cardiac muscle to altered conditions of haemodynamic overload caused by a large number of physiological and pathological conditions. Traditionally, it has been considered a beneficial mechanism. However, sustained hypertrophy has been associated with a significant increase in the risk of cardiovascular disease and mortality. Actually, many researchers are trying to understand whether left ventricular hypertrophy is a 'good' mechanism to stimulate or a 'bad' process to prevent. In this review we investigate the most common biochemical signaling pathways involved in the hypertrophic response to identify the precise role, either 'adaptive' or 'maladaptive', of each molecular pathway. Delinealing intracellular signaling pathways involved in the different aspects of cardiac hypertrophy will permit future improvements in the signaling that controls beneficial growth. Copryright 2004 European Society of Cardiology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15276462     DOI: 10.1016/j.cardiores.2004.04.031

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  47 in total

Review 1.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

Review 2.  Re-employment of developmental transcription factors in adult heart disease.

Authors:  Toru Oka; Jian Xu; Jeffery D Molkentin
Journal:  Semin Cell Dev Biol       Date:  2006-11-24       Impact factor: 7.727

Review 3.  Mitogen-activated protein kinases in heart development and diseases.

Authors:  Yibin Wang
Journal:  Circulation       Date:  2007-09-18       Impact factor: 29.690

4.  Exercise training as a treatment for heart failure: potential mechanisms and clinical implications.

Authors:  Begoña Benito; Stanley Nattel
Journal:  J Physiol       Date:  2009-11-01       Impact factor: 5.182

5.  Lack of Thy1 defines a pathogenic fraction of cardiac fibroblasts in heart failure.

Authors:  Yanzhen Li; Daniel Song; Lan Mao; Dennis M Abraham; Nenad Bursac
Journal:  Biomaterials       Date:  2020-01-29       Impact factor: 12.479

6.  UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy.

Authors:  Li Wang; Brian T Burmeister; Keven R Johnson; George S Baillie; Andrei V Karginov; Randal A Skidgel; John P O'Bryan; Graeme K Carnegie
Journal:  Cell Signal       Date:  2015-02-12       Impact factor: 4.315

Review 7.  Protein Kinase A as a Promising Target for Heart Failure Drug Development.

Authors:  Nancy S Saad; Mohammad T Elnakish; Amany A E Ahmed; Paul M L Janssen
Journal:  Arch Med Res       Date:  2019-01-11       Impact factor: 2.235

8.  Nrf2-Mediated Cardiac Maladaptive Remodeling and Dysfunction in a Setting of Autophagy Insufficiency.

Authors:  Qingyun Qin; Chen Qu; Ting Niu; Huimei Zang; Lei Qi; Linmao Lyu; Xuejun Wang; Mitzi Nagarkatti; Prakash Nagarkatti; Joseph S Janicki; Xing Li Wang; Taixing Cui
Journal:  Hypertension       Date:  2015-11-16       Impact factor: 10.190

9.  Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy.

Authors:  Maria Lajer; Anders Jorsal; Lise Tarnow; Hans-Henrik Parving; Peter Rossing
Journal:  Diabetes Care       Date:  2010-03-31       Impact factor: 17.152

10.  Over expression of Plk1 does not induce cell division in rat cardiac myocytes in vitro.

Authors:  Carmen H Coxon; Katrina A Bicknell; Fleur L Moseley; Gavin Brooks
Journal:  PLoS One       Date:  2009-08-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.